Latest Articles
Can GLP-1 Receptor Agonists Improve Outcomes in Patients at Risk for Endometrial Cancer? - Pharmacy Times
Can GLP-1 Receptor Agonists Improve Outcomes in Patients at Risk for Endometrial Cancer? Pharmacy Times
Published: May 22, 2026, 4:29 a.m.
Dostarlimab Combo Shows Durable Disease Control in dMMR/MSI-H Endometrial Cancer, Full Data Due at ASCO 2026 - OncLive
Dostarlimab Combo Shows Durable Disease Control in dMMR/MSI-H Endometrial Cancer, Full Data Due at ASCO 2026 OncLive
Published: May 22, 2026, 3:43 a.m.
ASCO 2026: Previewing Cervical and Endometrial Cancer Data - Medscape
ASCO 2026: Previewing Cervical and Endometrial Cancer Data Medscape
Published: May 21, 2026, 8:28 p.m.
Endometrial Cancer: Why The Patient’s Voice Needs To Be Part Of The Treatment Plan - SurvivorNet
Endometrial Cancer: Why The Patient’s Voice Needs To Be Part Of The Treatment Plan SurvivorNet
Published: May 21, 2026, 8:02 p.m.
New treatment offers hope for endometrial cancer patients - New York Post
New treatment offers hope for endometrial cancer patients New York Post
Published: May 20, 2026, 6:34 p.m.
How Investors Are Reacting To Merck (MRK) TroFuse ADC’s Breakthrough Endometrial Cancer Phase 3 Trial Results - Yahoo Finance
How Investors Are Reacting To Merck (MRK) TroFuse ADC’s Breakthrough Endometrial Cancer Phase 3 Trial Results Yahoo Finance
Published: May 20, 2026, 6:22 p.m.
Recognizing and Managing Immune-Related Adverse Events in Endometrial Cancer - OncLive
Recognizing and Managing Immune-Related Adverse Events in Endometrial Cancer OncLive
Published: May 20, 2026, 2:57 p.m.
New therapy bests chemo to improve survival in endometrial cancer - Rare Cancer News
New therapy bests chemo to improve survival in endometrial cancer Rare Cancer News
Published: May 20, 2026, 1:14 p.m.
GIST, SNUH identify beneficial bacterium linked to lower endometrial cancer recurrence - koreabiomed.com
GIST, SNUH identify beneficial bacterium linked to lower endometrial cancer recurrence koreabiomed.com
Published: May 20, 2026, 7:57 a.m.
Merck's Sac-TMT meets both endpoints in phase 3 endometrial cancer trial - MSN
Merck's Sac-TMT meets both endpoints in phase 3 endometrial cancer trial MSN
Published: May 20, 2026, 6:16 a.m.
Link copied to clipboard!